MX2016008214A - Tratamiento de esclerosis multiple con una combinacion de laquinimod y teriflunomida. - Google Patents
Tratamiento de esclerosis multiple con una combinacion de laquinimod y teriflunomida.Info
- Publication number
- MX2016008214A MX2016008214A MX2016008214A MX2016008214A MX2016008214A MX 2016008214 A MX2016008214 A MX 2016008214A MX 2016008214 A MX2016008214 A MX 2016008214A MX 2016008214 A MX2016008214 A MX 2016008214A MX 2016008214 A MX2016008214 A MX 2016008214A
- Authority
- MX
- Mexico
- Prior art keywords
- teriflunomide
- laquinimod
- combination
- cis
- presenting
- Prior art date
Links
- 201000006417 multiple sclerosis Diseases 0.000 title abstract 6
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 title abstract 5
- 229960004577 laquinimod Drugs 0.000 title abstract 5
- UTNUDOFZCWSZMS-YFHOEESVSA-N teriflunomide Chemical compound C\C(O)=C(/C#N)C(=O)NC1=CC=C(C(F)(F)F)C=C1 UTNUDOFZCWSZMS-YFHOEESVSA-N 0.000 title abstract 5
- 229960000331 teriflunomide Drugs 0.000 title abstract 5
- 206010071068 Clinically isolated syndrome Diseases 0.000 abstract 5
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención proporciona un método de tratamiento a un sujeto aquejado de esclerosis múltiple (EM) o que presenta un síndrome clínicamente aislado (CIS), que comprende administrar laquinimod al sujeto como parte de una terapia de combinación o para usarse directamente en combinación con una dosis superior a la mínima efectiva de teriflunomida. La presente invención también proporciona un paquete y una composición farmacéutica que comprende laquinimod y dosis superior a la mínima efectiva de teriflunomida para tratar un sujeto afligido con EM o que presenta un CIS. La presente invención también proporciona laquinimod para su uso como parte de una terapia de combinación o para usarse directamente en combinación con una dosis superior a la mínima efectiva de teriflunomida en el tratamiento de un sujeto que padece EM o que presenta un CIS. La presente invención proporciona además el uso de laquinimod y dosis superior a la mínima efectiva de teriflunomida en la preparación de una combinación para el tratamiento de un sujeto que padece EM o que presenta un CIS.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361920064P | 2013-12-23 | 2013-12-23 | |
| PCT/US2014/072244 WO2015100365A1 (en) | 2013-12-23 | 2014-12-23 | Treatment of multiple sclerosis with combination of laquinimod and teriflunomide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016008214A true MX2016008214A (es) | 2016-10-14 |
Family
ID=53479671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016008214A MX2016008214A (es) | 2013-12-23 | 2014-12-23 | Tratamiento de esclerosis multiple con una combinacion de laquinimod y teriflunomida. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20160317525A1 (es) |
| EP (1) | EP3086788A1 (es) |
| JP (1) | JP2017501230A (es) |
| AR (1) | AR098924A1 (es) |
| CA (1) | CA2933541A1 (es) |
| HK (1) | HK1227691A1 (es) |
| IL (1) | IL246078A0 (es) |
| MX (1) | MX2016008214A (es) |
| WO (1) | WO2015100365A1 (es) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100260716A1 (en) * | 2007-10-23 | 2010-10-14 | Ucb Pharma Gmbh | Compounds for treating demyelination conditions |
| TW201438738A (zh) * | 2008-09-16 | 2014-10-16 | 建南德克公司 | 治療進展型多發性硬化症之方法 |
| US20130197080A1 (en) * | 2010-08-02 | 2013-08-01 | Sanofi | Use of teriflunomide for treating multiple sclerosis |
| WO2013055907A1 (en) * | 2011-10-12 | 2013-04-18 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
| TW201804997A (zh) * | 2012-05-02 | 2018-02-16 | 以色列商泰瓦藥品工業有限公司 | 高劑量拉喹莫德(laquinimod)於治療多發性硬化症之用途 |
-
2014
- 2014-12-22 AR ARP140104868A patent/AR098924A1/es unknown
- 2014-12-23 US US15/107,450 patent/US20160317525A1/en not_active Abandoned
- 2014-12-23 CA CA2933541A patent/CA2933541A1/en not_active Abandoned
- 2014-12-23 MX MX2016008214A patent/MX2016008214A/es unknown
- 2014-12-23 EP EP14875012.8A patent/EP3086788A1/en not_active Withdrawn
- 2014-12-23 HK HK16114336.6A patent/HK1227691A1/zh unknown
- 2014-12-23 WO PCT/US2014/072244 patent/WO2015100365A1/en not_active Ceased
- 2014-12-23 JP JP2016560885A patent/JP2017501230A/ja active Pending
-
2016
- 2016-06-07 IL IL246078A patent/IL246078A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK1227691A1 (zh) | 2017-10-27 |
| EP3086788A1 (en) | 2016-11-02 |
| JP2017501230A (ja) | 2017-01-12 |
| CA2933541A1 (en) | 2015-07-02 |
| IL246078A0 (en) | 2016-07-31 |
| WO2015100365A1 (en) | 2015-07-02 |
| AR098924A1 (es) | 2016-06-22 |
| US20160317525A1 (en) | 2016-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2014001050A (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero. | |
| HK1199820A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and fingolimod | |
| HK1205941A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate | |
| HK1198278A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and interferon-beta | |
| MX2021000071A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| MX387885B (es) | Inhibidores de ezh2 para tratar linfomas. | |
| SG10201810888XA (en) | Compositions and methods comprising bupropion or related compounds and dextromethorphan | |
| NZ700759A (en) | Combination therapy for treating cancer | |
| IN2015DN03219A (es) | ||
| EA201691155A1 (ru) | Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств | |
| MX2015010296A (es) | Tratamiento de formas progresivas de esclerosis multiple con laquinimod. | |
| PH12016502355A1 (en) | Pharmaceutical composition | |
| PH12016502352A1 (en) | Pharmaceutical composition | |
| TW201613578A (en) | Pharmaceutical combinations | |
| MX2015000485A (es) | Tratamiento de esclerosis multiple con una combinacion de laquinimod y fampridina. | |
| MX2015000398A (es) | Formulaciones de laquinimod sin agente alcalinizante. | |
| MY197664A (en) | Immunity enhancing agent for cancer by allergin-1 antagonist | |
| MX2021014120A (es) | Tratamiento de los sintomas asociados a terapia privacion de androgenos. | |
| MX2016001177A (es) | Tratamiento de esclerosis multiple con la combinacion de laquinimod y flupirtina. | |
| MX2016008214A (es) | Tratamiento de esclerosis multiple con una combinacion de laquinimod y teriflunomida. | |
| MX2014013491A (es) | Metodos para mantener, tratar o mejorar la funcion cognitiva. | |
| MX2016003763A (es) | Terapia de combinacion con laquinimod para tratamiento de esclerosis multiple. | |
| PH12014500252A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and glatiramer acetate | |
| MX2016001179A (es) | Tratamiento de esclerosis multiple por induccion de alemtuzumab seguido por terapia de laquinimod. | |
| IN2013MU01155A (es) |